article thumbnail

Archive

Drug Discovery World

2019 Archive 2018 Archive 2017 Archive 2016 Archive 2015 Archive 2014 Archive 2013 Archive 2012 Archive 2011 Archive 2010 Archive 2009 Archive 2008 Archive 2007 Archive 2006 Archive 2005 Archive 2004 Archive 2003 Archive 2002 Archive 2001 Archive 2000 Archive The post Archive appeared first on Drug Discovery World (DDW).

Drugs 130
article thumbnail

This week in drug discovery (6-10 March)

Drug Discovery World

Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE). News round-up for 6-10 March by DDW Digital Content Editor Diana Spencer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The regulatory round-up: Eight key FDA decisions

Drug Discovery World

Read more: ADC potential “standard of care” for some breast cancer patients NTLA-2002, Intellia Therapeutics The FDA cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE) in March.

FDA 130
article thumbnail

Study shines a light on representation in clinical research

Drug Discovery World

GSK’s retrospective study looked at clinical trial demographic data from 495 GSK and ViiV clinical trials involving US-based participants from the period 2002 to 2019.

article thumbnail

DDW Highlights: 13 March 2023

Drug Discovery World

Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE). DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.

article thumbnail

DDW Highlights: 13 March 2023

Drug Discovery World

Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE). DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.

article thumbnail

Podcast: Key stories from the drug discovery industry

Drug Discovery World

Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE). DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.